Literature DB >> 7589026

Functional capacity in healthy volunteers before and following beta-blockade with controlled-release metoprolol.

P K Rønnevik1, J E Nordrehaug, G von der Lippe.   

Abstract

The effects of the beta 1-selective beta-adrenergic blocker metoprolol on physiological responses, exercise capacity and gas exchange parameters were measured in healthy men using different graded bicycle exercise protocols on separate days before and following administration of 200 mg controlled-release metoprolol. Eleven men performed in randomised order maximal cardiopulmonary exercise testing on 50-W/6-min stage, 50-W/3-min stage and ramp (15-W/min-1) protocols. Peak heart rate and peak heart rate-blood pressure products were similar on all exercise protocols, and were significantly reduced by metoprolol. Submaximal and peak oxygen consumption were similar before and following beta-adrenoceptor blockade. Depending on the exercise protocol applied, an insignificant decrease of 4-10% in maximal cumulated exercise capacity (work-rate x time integral) was observed following administration of metoprolol. It is concluded that in healthy men evaluated with different exercise protocols the beta 1-selective controlled-release beta-adrenoceptor blocker metoprolol does not influence exercise capacity despite a marked reduction of heart rate and rate-pressure product.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589026     DOI: 10.1007/BF00192737

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  DETECTING THE THRESHOLD OF ANAEROBIC METABOLISM IN CARDIAC PATIENTS DURING EXERCISE.

Authors:  K WASSERMAN; M B MCILROY
Journal:  Am J Cardiol       Date:  1964-12       Impact factor: 2.778

2.  A comparison of the reproducibility and physiologic response to three maximal treadmill exercise protocols.

Authors:  V F Froelicher; H Brammell; G Davis; I Noguera; A Stewart; M C Lancaster
Journal:  Chest       Date:  1974-05       Impact factor: 9.410

Review 3.  beta-Adrenoceptor blockade and exercise: effects on endurance and physical training.

Authors:  A Juhlin-Dannfelt
Journal:  Acta Med Scand Suppl       Date:  1983

4.  Cardiopulmonary exercise testing. The clinical value of gas exchange data.

Authors:  G W Neuberg; S H Friedman; M B Weiss; M V Herman
Journal:  Arch Intern Med       Date:  1988-10

Review 5.  Beta-adrenoceptor blockade and exercise. An update.

Authors:  M A Van Baak
Journal:  Sports Med       Date:  1988-04       Impact factor: 11.136

6.  Difference between beta-1-selective and non-selective beta-blockade during continuous and intermittent exercise.

Authors:  L Gullestad; L O Dolva; E Søyland; J Kjekshus
Journal:  Clin Physiol       Date:  1988-10

7.  Effect of sympathomimetic compounds with beta-adrenergic effects on plasma free fatty acids in man.

Authors:  T R Pilkington; R D Lowe; R Foster; B F Robinson; A Antonis
Journal:  J Lipid Res       Date:  1966-01       Impact factor: 5.922

8.  The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily.

Authors:  K Egstrup; T Gundersen; R Härkönen; E Karlsson; B Lundgren
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

9.  Efficacy and tolerability of a new controlled-release formulation of metoprolol: a comparison with conventional metoprolol tablets in mild to moderate hypertension.

Authors:  J J Houtzagers; J G Smilde; G Creytens; G Westergren
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Optimizing the exercise protocol for cardiopulmonary assessment.

Authors:  M J Buchfuhrer; J E Hansen; T E Robinson; D Y Sue; K Wasserman; B J Whipp
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1983-11
View more
  1 in total

1.  The effects of beta1-adrenergic blockade on cardiovascular oxygen flow in normoxic and hypoxic humans at exercise.

Authors:  Guido Ferretti; Marc J Licker; Sara Anchisi; Christian Moia; Davide Susta; Denis R Morel
Journal:  Eur J Appl Physiol       Date:  2005-10-01       Impact factor: 3.078

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.